David E. Gunn
Bayer
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by David E. Gunn.
Bioorganic & Medicinal Chemistry Letters | 2001
Aniko Redman; Jeffrey S Johnson; Robert Dally; Steve Swartz; Hanno Wild; Holger Paulsen; Yolanda V Caringal; David E. Gunn; Joel Renick; Martin Osterhout; Jill Kingery-Wood; Roger A. Smith; Wendy Lee; Jacques Dumas; Scott Wilhelm; Timothy J Housley; Ajay Bhargava; Gerald Ranges; Alka Shrikhande; Deborah Young; Michael Bombara; William J. Scott
Inhibitors of the MAP kinase p38 are potentially useful for the treatment for osteoporosis, arthritis, and other inflammatory diseases. A series of thienyl, furyl, and pyrrolyl ureas has been identified as potent p38 inhibitors, displaying in vitro activity in the nanomolar range.
Bioorganic & Medicinal Chemistry Letters | 1998
Nan-Horng Lin; David E. Gunn; Yihong Li; Yun He; Hao Bai; Keith B. Ryther; Theresa A. Kuntzweiler; Diana L. Donnelly-Roberts; David J. Anderson; Jeffrey E. Campbell; James P. Sullivan; Stephen P. Arneric; Mark W. Holladay
Analogs of 3-[2-((S)-pyrrolidinyl)methoxy]pyridine, (A-84543, 1) with 2-, 4-, 5-, and 6-substituents on the pyridine ring were synthesized. These analogs exhibited Ki values ranging from 0.15 to > 9,000 nM when tested in vitro for neuronal nicotinic acetylcholine receptor binding activity. Assessment of functional activity at subtypes of neuronal nicotinic acetylcholine receptors indicates that pyridine substitution can have a profound effect on efficacy at these subtypes, and several subtype-selective agonists and antagonists have been identified.
Bioorganic & Medicinal Chemistry Letters | 1996
Richard L. Elliott; Hana Kopecka; David E. Gunn; Nan-Horng Lin; David S. Garvey; Keith B. Ryther; Mark W. Holladay; David J. Anderson; Jeffrey E. Campbell; James P. Sullivan; Michael J. Buckley; Karen L. Gunther; Alyssa B. O'Neill; Michael W. Decker; Stephen P. Arneric
Abstract A series of 2-(aryloxymethyl) azetidine and pyrrolidine nAChR ligands in which the 3-pyridyl moiety of a previously described series 1 was replaced by a substituted phenyl group was explored. Aromatic substitution afforded analogues with K i values ranging from 3 to >10,000 nM. Generally, substitution at the ortho - and para -position was unfavorable, whereas electron-withdrawing groups at the meta -position improved the K i values.
Bioorganic & Medicinal Chemistry Letters | 1999
Nan-Horng Lin; Melwyn Abreo; David E. Gunn; Suzanne A. Lebold; Edmund L. Lee; James T. Wasicak; Ann-Marie Hettinger; Jerome F. Daanen; David S. Garvey; Jeffrey E. Campbell; James P. Sullivan; Michael D. Williams; Stephen P. Arneric
Analogs of compound 1 with a variety of azacycles and heteroaryl groups were synthesized. These analogs exhibited Ki values ranging from 0.15 to > 10,000 nM when tested in vitro for cholinergic channel receptor binding activity (displacement of [3H](-) cytisine from whole rat brain synaptic membranes).
Journal of Medicinal Chemistry | 1996
Melwyn Abreo; Nan-Horng Lin; David S. Garvey; David E. Gunn; Ann-Marie Hettinger; James T. Wasicak; Patricia A. Pavlik; Yvonne C. Martin; Diana L. Donnelly-Roberts; David J. Anderson; James P. Sullivan; Michael T. Williams; Stephen P. Arneric; Mark W. Holladay
Archive | 1998
Scott Miller; Martin Osterhout; Jacques Dumas; Uday Khire; Timothy B. Lowinger; William J. Scott; Roger A. Smith; Jill E. Wood; David E. Gunn; Holia Hatoum-Mokdad; Marell Rodriguez; Robert Sibley; Ming Wang; Tiffany Turner; Catherine Brennan
Archive | 1998
Scott Miller; Martin Osterhout; Jacques Dumas; Uday Khire; Timothy B. Lowinger; Bernd Riedl; William J. Scott; Roger A. Smith; Jill E. Wood; David E. Gunn; Ming Wang; Tiffany Turner; Catherine Brennan
Archive | 2002
Jacques Dumas; Bernd Riedl; Uday Khire; Robert Sibley; Holia Hatoum-Mokdad; Mary-Katherine Monahan; David E. Gunn; Timotthy B. Lowinger; William J. Scott; Roger A. Smith; Jill E. Wood
Archive | 1993
Melwyn Abreo; David E. Gunn; Nan-Horng Lin; Richard L. Elliott; David S. Garvey; Suzanne A. Lebold; James T. Wasicak
Journal of Pharmacology and Experimental Therapeutics | 1997
James P. Sullivan; Diana L. Donnelly-Roberts; Clark A. Briggs; David J. Anderson; Murali Gopalakrishnan; Iris C. Xue; Marietta Piattoni-Kaplan; Eduardo J. Molinari; Jeffrey E. Campbell; David G. McKenna; David E. Gunn; Nan-Horng Lin; Keith B. Ryther; Yun He; Mark W. Holladay; Susan Wonnacott; Michael Williams; Stephen P. Arneric